首页/数据集/Supplementary Table S1-S6 from The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells

Supplementary Table S1-S6 from The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells

NIAID Data Ecosystem2026-04-25 收录

肿瘤耐药机制

AML靶向治疗

数据链接：

https://figshare.com/articles/dataset/Supplementary_Table_S1-S6_from_The_TP53_Apoptotic_Network_Is_a_Primary_Mediator_of_Resistance_to_BCL2_Inhibition_in_AML_Cells/22536115 数据链接链接失效反馈

官方服务：

资源简介：

Supplementary Data Tables

应用场景：

创建时间：

2019-07-01

肿瘤耐药机制

组合治疗

EGFR-mut NSCLC lines show differential suceptibility to inhibition of tankyrase in the presence of EGFR inhibitors Overall design: NSCLC cells were treated in quadruplicate with gefitinib, AZ1366 (tan

NIAID Data Ecosystem80

Ploidy variations between secondary resistant and parental soft-tissue sarcoma cell lines.

肿瘤耐药机制

细胞倍性分析

only sensitive cloneonly resistant clone-: absence of allelic imbalancePloidy variations between secondary resistant and parental soft-tissue sarcoma cell lines.

Figshare2015-12-03 更新50

LncRNA-42060 Regulates Tamoxifen Sensitivity and Tumor Development via Regulating the miR-204-5p/SOX4 Axis in Canine Mammary Gland Tumor Cells

肿瘤耐药机制

非编码RNA调控

Tamoxifen is the drug of choice for endocrine therapy of breast cancer. Its clinical use is limited by the development of drug resistance. There is increasing evidence that long non-coding RNAs (lncRN

NIAID Data Ecosystem30

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

肿瘤耐药机制

信号通路靶向治疗

BackgroundThe sustained clinical activity of the BRAF inhibitor vemurafenib (PLX4032/RG7204) in patients with BRAFV600 mutant melanoma is limited primarily by the development of acquired resistance le

Figshare2016-01-18 更新50

Development of Dual FLT3 and CHK1 PROTACs for the Treatment of AML

AML靶向治疗

PROTAC药物设计

FLT3 inhibitors (FLT3i) are effective for treating acute myeloid leukemia (AML), but acquired and adaptive resistance pose significant challenges. Therefore, finding a novel AML therapy that overcomes

NIAID Data Ecosystem40

Supplementary Table S1-S6 from The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells

资源简介：

相关数据集